在患有心力衰竭或有心力衰竭风险的患者中,但在首次住院治疗之前,增长差异化因子-15
Joshua Bradley1,2, Erik B Schelbert3,4, Laura J Bonnett5
1Division of Cardiovascular Sciences, The University of Manchester, Manchester, UK.
Heart (British Cardiac Society)
|August 11, 2023
概括
增长差异化因子 (GDF) -15是心力衰竭 (HF) 风险患者不良结果的强有力的预测因子. 测量GDF-15可以改善HF住院或死亡的早期风险分层.
科学领域:
- 心脏病学 心脏病学
- 生物标志物 生物标志物
- 心脏衰竭研究研究
背景情况:
- 早期识别患有心力衰竭 (HF) 副作用风险的患者至关重要.
- 增长差异化因子 (GDF) -15是HF风险评估的潜在生物标志物.
研究的目的:
- 确定循环GDF-15.5的决定因素.
- 评估GDF-15在患有HF风险或早期HF的患者的预后价值.
主要方法:
- 对2166名患者进行的前性纵向队列研究.
- 心血管磁共振和GDF-15测量. 这是一个很好的方法.
- 使用多变量回归和生存分析 (Cox,NRI,DCA).
主要成果:
- 年龄,糖尿病和NT-proBNP是GDF-15的主要决定因素,解释了51%的变化.
- 日志转换的GDF-15是HF住院或全因死亡率 (HR 2.12) 的最强预测因素.
- GDF-15显著改善了风险预测模型 (NRI 0.26) 和临床决策.
结论:
- GDF-15在患有或早期HF风险的患者中提供独特的预后信息.
- 它对HF住院和全因死亡率的高度预测性.
- GDF-15提高了风险分层的准确性,有助于临床决策.
相关概念视频
Heart Failure IV: Classification and Diagnostic Evaluation
19
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
19
Heart Failure V: Medical Management
13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure II: Pathophysiology
15
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
15


